Related references
Note: Only part of the references are listed.Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra et al.
NATURE COMMUNICATIONS (2020)
Radiation-induced heart disease: a review of classification, mechanism and prevention
Heru Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
Joe Mehanna et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2019)
PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Dalia Kamel et al.
CURRENT DRUG TARGETS (2018)
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study
Reshma Jagsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Mathieu Cesaire et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats
Sevil Korkmaz-Icoez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
Jian xin Zhou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
Paul Lesueur et al.
ONCOTARGET (2017)
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy
Shannon K. Swisher et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Statistical controversies in clinical research: requiem for the 3+3 design for phase I trials
X. Paoletti et al.
ANNALS OF ONCOLOGY (2015)
The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice
Ciric To et al.
CANCER PREVENTION RESEARCH (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment
Cyrus Chargari et al.
CANCER TREATMENT REVIEWS (2011)
Share Paper
